Compositions and methods for inhibition of lineage specific antigens
AssigneeThe Trustees of Columbia University in the City of New York
InventorsSiddhartha Mukherjee, Florence Borot, Abdullah Mahmood Ali
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods of administering an agent targeting a lineage-specific cell-surface antigen and a population of hematopoietic cells that are deficient in the lineage-specific cell-surface antigen for immunotherapy of hematological malignancies.
Claims30
A genetically engineered human hematopoietic cell that is engineered such that it is deficient in a lineage-specific cell-surface antigen which is expressed by its naturally-occurring hematopoietic cell counterpart, wherein the lineage-specific cell-surface antigen is not required for survival of a human subject.
Dependencies are inferred from the claim text.